US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist
  • 1015.670
  • +16.650+1.67%
Close Oct 11 16:00 ET
  • 1015.670
  • 0.0000.00%
Post 20:02 ET
111.96BMarket Cap26.89P/E (TTM)

Regeneron Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Regeneron Pharmaceuticals Q3 2024 Estimates Date

Currency：USDOct 31, 2024

Estimate YoY
Revenue
3.66B
+8.90%
EPS
9.37
+5.41%
Analyst Rating
Strong Buy

Oct 12, 2024

Regeneron Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 20 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 3.790B--
Oct 31, 20242024/Q3-- / 3.662B--
Aug 1, 20242024/Q23.547B / 3.387B--
May 2, 20242024/Q13.145B / 3.221B--
Feb 2, 20242023/Q43.434B / 3.287B--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 3.790B--
Oct 31, 20242024/Q3-- / 3.662B--
Aug 1, 20242024/Q23.547B / 3.387B--
May 2, 20242024/Q13.145B / 3.221B--
Feb 2, 20242023/Q43.434B / 3.287B--

Unlock Free Earnings Estimates

Regeneron Pharmaceuticals Earnings Reports

  • Regeneron Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

    Aug 1 07:21 ET

  • Regeneron Pharmaceuticals | 10-Q: Q1 2024 Earnings Report

    May 2 07:18 ET

  • Regeneron Pharmaceuticals | 10-K: FY2023 Annual Report

    Feb 5 09:17 ET

  • Regeneron Pharmaceuticals | 10-Q: Q3 2023 Earnings Report

    Nov 2, 2023 07:22 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Oct 12, 2024

    Strong Buy

    • Buy

      90.48%

    • Hold

      4.76%

    • Sell

      4.76%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data

    Concept Infectious Disease
    Infectious Disease
    Intraday0.00%